27 Jun. 2011
WILMINGTON, N.C., (June 27, 2011) - PPD, Inc. (Nasdaq: PPDI) today announced it has appointed Edward Ian as vice president of clinical development for Asia Pacific. Mr. Ian will be based in Singapore and will provide strategic leadership and operational oversight for PPD's Phase II-IV business in the region.
"Edward Ian brings more than 15 years of clinical operations, central laboratory management, quality management systems and project management expertise through his long tenure with multinational companies in Asia Pacific and the United States," said Paul Colvin, executive vice president of global clinical development at PPD. "His expertise across a wide range of areas within the clinical research industry will play a significant role in advancing our strong position in this growing region."
Mr. Ian spent six years at a large, global contract research organization where he most recently served as executive director of scientific affairs responsible for Phase I-IV clinical operations in Asia Pacific. He also held the positions of regional director of operations and senior director of clinical operations for Asia Pacific, where he managed daily operations, set strategy and performance standards, and collaborated on business development initiatives. He began his career as a laboratory scientist and later served as director of business development and quality assurance for a regional CRO in Taiwan where he rose to executive vice president.
Mr. Ian earned his executive master's of business administration from National Chengchi University in Taipei, Taiwan, and his bachelor of science in medical technology from Central Missouri State University in Warrensburg, Mo.
PPD is one of the largest CROs operating in Asia Pacific with nearly 1,400 people and offices in 13 countries. The company offers a full range of drug discovery and development services from the region, including operating global central laboratories in China and Singapore.